Meeting
2019 Gastrointestinal Cancers Symposium
Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer treated with gemcitabine and nab-paclitaxel.
Authors
Motoyasu Kan
National Cancer Center Hospital East, Chiba, Japan
Motoyasu Kan , Hiroshi Imaoka , Masafumi Ikeda , Shuichi Mitsunaga , Izumi Ohno , Yusuke Hashimoto , Mitsuhito Sasaki , Hideaki Takahashi , Kazuo Watanabe , Kumiko Umemoto , Gen Kimura , Taro Shibuki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 324)
DOI
10.1200/JCO.2019.37.4_suppl.324
Abstract #
324
Poster Bd #
H2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical significance of CA125 in unresectable pancreatic cancer treated with first-line chemotherapy.
First Author: Iori Motoo
Poster
2019 Gastrointestinal Cancers Symposium
Impact of glycemic control on treatment efficacy and safety during nabpaclitaxel plus gemcitabine therapy in unresectable pancreatic cancer.
First Author: Junko Tauchi
Poster
2017 Gastrointestinal Cancers Symposium
Effect of advanced age, elevated bilirubin, and disease extent on outcomes of unresectable pancreatic cancer (UPC) patients receiving first-line chemotherapy: A population-based study.
First Author: Hannah Marie Cherniawsky
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Depth of response in patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory subgroup analysis of JCOG1407.
First Author: Taro Shibuki